drugset / Trial / NCT06975813

Magnesium Sulfate and Trigger Points

NCT06975813

Phase 2 Not yet recruiting 30 enrolled Fayoum University
RandomizedParallel-groupSingle-blindTreatment

Summary

The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever

Timeline

Start
2025-06-01
Primary completion
2025-12-30
Completion
2026-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 0.5 ml Other